Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Cimlanod (Primary) ; Nitroglycerin
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 23 Feb 2021 Results comparing effects of the HNO donor cimlanod (BMS-986231) with those of nitroglycerin (NTG) or placebo on cardiac function in patients with chronic heart failure with reduced ejection fraction (HFrEF) published in the European Journal of Heart Failure
- 30 Mar 2020 Primary endpoint has been met. (Left Ventricle Stroke Volume Index (SVI))
- 30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology